

## NEW AZOMETHINE CARDENOLIDE GLYCOSIDES

S. V. Kovalev

UDC 547.92/93+615.224:547.918

*New azomethines (aldimines) were synthesized from cardiac glycosides erysimin and cymarín. The structures of the new compounds were confirmed by PMR spectra and elemental analysis.*

**Key words:** azomethines, aldimines, cardenolide glycosides, erysimin, cymarín, amines.

Azomethines are comparatively nontoxic compounds [1]. Therefore, the toxicity of natural cardiac glycosides may possibly be reduced by preparing them. In continuation of this research [1, 2], we prepared new azomethines of the cardiac glycosides erysimin and cymarín (**1**, **2**, **5-10**, **12**, **14**) and semicarbazones (**3** and **11**) and hydrazones (**4** and **13**) related to them.

The synthesis was performed mainly using the literature method [1-3] of direct reaction of aldehyde glycosides and primary amines with boiling in solvents that enable the removal of water as an azeotrope. Of all reagents used, aminoalkylpyridines formed the azomethines most completely and quickly, which led to the use of pyridine as a catalyst, the use of which for these purposes was first proposed by Gubin and Makarevich [4].

In fact, small additions of pyridine (see Experimental) accelerated the reaction. A second factor that increased the rate of the reaction and the yield of the target azomethines was performing the synthesis at high concentrations of reagents, according to recommendations in the literature [5].

In some instances the reaction products could be crystallized directly after the synthesis. However, chromatographic purification over columns of  $\text{Al}_2\text{O}_3$  or  $\text{SiO}_2$  was required more often than not.

Only one of the two geometric isomers that are possible in principle based on the different location of the functional groups around the  $\text{C}=\text{N}$  double bond was obtained in practice. We believe as before [3] that this is the *trans*-isomer. This is consistent with the PMR spectra and the ability of the obtained azomethines to form complexes with Cu ions. Only the *trans*-isomer with the chelating structure consisting of the  $5\beta\text{-OH}$ , the C-3 O atom, and the unshared electron pair on N that is oriented toward the first two groups can form a complex with Cu ions.

The PMR spectra of the obtained azomethines have the signal for the angular methyl  $18\text{-CH}_3$  at 0.66-0.73 ppm, i.e., shifted to strong field due to the steric effect on it of the  $19\text{C-H}$  proton, i.e., the  $19\text{C-H}$  proton is oriented toward this methyl. These data agree with the literature [3] relative to the stereochemistry of aldimines of cardenolides. Figure 1 shows the PMR spectrum.






Fig. 1. PMR spectrum of benzyliminocymarín.

TABLE 1. Azomethines of Erysimin and Cymarin

Compound	R <sub>2</sub>	Molecular formula	mp, °C	[α] <sub>D</sub> <sup>20</sup> in MeOH
1	CH <sub>3</sub>	C <sub>36</sub> H <sub>48</sub> N <sub>2</sub> O <sub>8</sub>	132-134	+51.8±2
2	CH <sub>3</sub>	C <sub>36</sub> H <sub>48</sub> N <sub>2</sub> O <sub>8</sub>	142-144	+49.9±2
3	CH <sub>3</sub>	C <sub>31</sub> H <sub>44</sub> N <sub>3</sub> O <sub>9</sub>	147-150/172-174	+42.4±2
4	CH <sub>3</sub>	C <sub>36</sub> H <sub>48</sub> N <sub>2</sub> O <sub>8</sub>	111-114	+78.1±3
5	CH <sub>3</sub>	C <sub>37</sub> H <sub>49</sub> NO <sub>8</sub>	109-110/127-129	+65.3±2
6	CH <sub>3</sub>	C <sub>32</sub> H <sub>46</sub> NO <sub>9</sub>	139-142	+47.7±2
7	CH <sub>3</sub>	C <sub>33</sub> H <sub>48</sub> NO <sub>9</sub>	135-138	+36.9±3
8	CH <sub>3</sub>	C <sub>36</sub> H <sub>48</sub> N <sub>2</sub> O <sub>8</sub>	118-121	+66.7±3
9	CH <sub>3</sub>	C <sub>34</sub> H <sub>45</sub> NO <sub>9</sub>	130-132	+60.1±3
10	CH <sub>3</sub>	C <sub>36</sub> H <sub>49</sub> N <sub>2</sub> O <sub>9</sub>	107-109	+44.3±3
11	H	C <sub>30</sub> H <sub>42</sub> N <sub>3</sub> O <sub>9</sub>	273-275	+54.8±3
12	H	C <sub>36</sub> H <sub>49</sub> NO <sub>9</sub>	120-122	+20.2±3
13	H	C <sub>33</sub> H <sub>43</sub> N <sub>2</sub> O <sub>9</sub>	115-117	+26.3±3
14	H	C <sub>35</sub> H <sub>50</sub> NO <sub>9</sub>	140-142	+27.5±3



## EXPERIMENTAL

The course of reactions and purity of compounds were monitored using TLC on Sorbfil plates and CHCl<sub>3</sub>:CH<sub>3</sub>OH:H<sub>2</sub>O (85:15:0.7) with development by Raymond reagent. Melting points were determined on a Kofler block. PMR spectra were recorded on a Varian VX-200. Elemental analyses were measured on an automated C—H—N—S analyzer and agreed with those calculated.

**Benzyliminocymarin (5).** Cymarin (1.5 g) was dissolved in benzene:isopropanol (3:1, 25 mL) and treated with benzylamine (C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>NH<sub>2</sub>, 0.44 g, 1.5-fold excess of calc.). The mixture was boiled for 2 h in a long-necked flask, periodically adding evaporating solvent. The solution was concentrated to about 3 mL and treated with anhydrous pyridine (5 drops). The reaction was continued, adding benzene (1 mL) every 10-15 min. After the reaction was completed and the solution was cooled to room temperature, nefras (35 mL, bp 170-195°C) was added. The mixture was stirred. The nefras solution was decanted. The thick mass was ground three times with nefras (15 mL) until it turned into a powder. This transferred the benzylamine into the nefras. The resulting crude benzyloiminocymarin (1.7 g) was chromatographed over an Al<sub>2</sub>O<sub>3</sub> column (50.0 g Al<sub>2</sub>O<sub>3</sub>, Brockmann activity III).

The eluents were  $\text{CHCl}_3$  and  $\text{CHCl}_3:\text{CH}_3\text{OH}$  of increasing polarity. Fractions containing pure cymarin azomethine were crystallized from  $\text{CH}_2\text{Cl}_2$ :nefrase to afford **5** (1.04 g, 60% of calc.),  $\text{C}_{37}\text{H}_{49}\text{NO}_8$ , mp 109-110/127-129°C,  $[\alpha]_{\text{D}} +65.3 \pm 2^\circ$  (*c* 0.8,  $\text{CH}_3\text{OH}$ ).

The remaining azomethines of cymarin and erysimin were synthesized analogously. Table 1 gives their properties.

## REFERENCES

1. I. F. Makarevich and S. V. Kovalev, *Khim. Prir. Soedin.*, 185 (1998).
2. I. F. Makarevich, Yu. I. Gubin, M. V. Mokrouz, S. V. Kovalev, T. V. Slyusarskaya, and K. V. Zhernoklev, *Farmakom*, No. 2, 36 (2001).
3. I. F. Makarevich, Yu. I. Gubin, and R. Megges, *Khim. Prir. Soedin.*, 332 (2005).
4. Yu. I. Gubin and I. F. Makarevich, *Khim. Prir. Soedin.*, 381 (2006).
5. I. F. Makarevich, Yu. I. Gubin, and R. Megges, *Khim. Prir. Soedin.*, 42 (2005).